Telix's new ra­dio­phar­ma spin­out banks on one tri­al for suc­cess, CEO says

The fu­ture of Telix Phar­ma­ceu­ti­cals’ new spin­out Rhine Phar­ma hinges on the out­come of one ear­ly-stage tri­al, Telix CEO Chris­t­ian Behren­bruch told End­points News in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER